Cancer research UK (CRUK) Manchester Institute
host : L. Le CAM (IRCM)
Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta
host : Alexandre Djiane (IRCM)
Physiological Sciences Department, Faculty of Science, Stellenbosch University, South Africa.
Resia Pretorius is a Distinguished Professor at Stellenbosch University (South Africa), Honorary Professor at the University of Liverpool, and founding director of Biocode Technologies. Her research focuses on how inflammation disrupts coagulation and immune function, leading to microclots, platelet activation, and endothelial pathology across diseases including cancer, diabetes, cardiovascular disease and Long COVID. She has published over 330 papers, filed multiple patents on microclot diagnostics, and serves on global health advisory panels including the WHO.
host : Alain R. Thierry (IRCM)
Senior Lecturer,
City St George's, University of London
host : (N. Bonnefoy, IRCM)
selected publications :
Bacevic K*, Noble R*, Soffar A, Ammar OW, Boszonyik B, Prieto S, Vincent C, Hochberg ME, Krasinska L, Fisher D. Spatial competition constrains resistance to targeted cancer therapy. Nature Communications (2017) 8, 1995
Viossat Y, Noble R. A theoretical analysis of tumour containment. Nature Ecology & Evolution (2021)
Patil S, Viossat Y, Noble R. Preventing evolutionary rescue in cancer. bioRxiv (2023)
Université Libre de Bruxelles
host : Laurent Le Cam (IRCM)
https://orcid.org/0000-0001-8857-2609
Department of Translational Research and New Technologies in Medicine, University of Pisa, Italy.
hôte : Andrei TURTOI (IRCM)
Institute for Radiation Sciences, Osaka University, Japan
Professor Kazuya Kabayama leads the Laboratory for Radiation Chemical Biology at Osaka University, where his research bridges chemistry, cellular biology, and nuclear medicine. His primary focus is on developing innovative treatments in radiotherapy, particularly targeted alpha therapy (TAT) using astatine-211 (211At), a promising alpha-emitting radionuclide for the treatment of resistant cancers. Professor Kabayama has contributed significantly to the design and synthesis of 211At-labeled compounds aimed at first-in-human clinical trials. He has also participated in studies exploring 211At-labeled gold nanoparticles, demonstrating their potent antitumor effects. His work plays a key role in advancing the clinical translation of alpha-based radiopharmaceuticals. In parallel, his research investigates molecular interactions involving lipids and glycans, especially in the context of innate immunity and diseases such as cancer and diabetes. His team develops real-time cellular imaging tools to analyze the dynamics of glycolipids and multivalent glycan-receptor interactions at the membrane level. Through a highly interdisciplinary approach combining organic chemistry, radiobiology, and molecular imaging, Professor Kabayama contributes to the advancement of targeted therapies and the fundamental understanding of complex disease mechanisms. His work positions him at the forefront of innovation in both therapeutic and diagnostic strategies in nuclear medicine.
host : Jean-Pierre POUGET (IRCM)
Institut de Génomique Fonctionnelle de Lyon (IGFL), UMR 5242 CNRS / E.N.S. de Lyon (France)
hôte : Alexandre DJIANE et Jennifer FALCONI (IRCM-Inserm)
Situé dans le Parc Euromédecine, l'Institut de Recherche en Cancérologie de Montpellier (U1194) est localisé sur le Campus Val d'Aurelle (ICM, Institut régional du Cancer Montpellier / Val d'Aurelle).
Centre de Recherche U1194 soutenu par l'Inserm, l'Université de Montpellier et l'Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de
